StephenDominicAradiMD(He/Him)

Neurology • Tampa, FL

Movement Disorder

Assistant Professor of Neurology; Co-Director, HDSA Huntington Disease Center of Excellence at USF

Join to view full profile

Dr. Aradi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Aradi's full profile

Already have an account?

Office
13220 USF Laurel Drive
MDC 55
Tampa, FL 66312
Phone+1 813-396-7138

Fax+1 813-978-8032
Is this information wrong?

Education & Training

University of South Florida Morsani College of MedicineFellowship, Movement Disorders, 2019 - 2020
University of Pennsylvania Health SystemResidency, Neurology, 2016 - 2019
University of Pennsylvania Health SystemInternship, Internal Medicine, 2015 - 2016
University of South Florida College of MedicineClass of 2015

Certifications & Licensure

FL State Medical License 2019 - 2025
PA State Medical License 2015 - 2019
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Steven L. Galetta Resident Teaching Award University of Pennsylvania Department of Neurology, 2019
Inductee Alpha Omega Alpha Honor Medical Society

Clinical Trials

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort Start of enrollment: 2012 Jul 01
Recruiting
Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight Into Parkinson's Disease Status Start of enrollment: 2017 May 17
Active, not recruiting
Not Applicable
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease Start of enrollment: 2019 Jan 23
Completed
Phase 3
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies Start of enrollment: 2019 Apr 23
Completed
Phase 3
PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD Start of enrollment: 2020 Oct 16
Active, not recruiting
Phase 3
HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States Start of enrollment: 2020 Jun 21
Completed
Development of the Virtual Unified Huntington's Disease Rating Scale Start of enrollment: 2022 Sep 22
Completed
Roles: Contact
Automated Imaging Differentiation of Parkinsonism Start of enrollment: 2021 Jul 22
Recruiting
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease. Start of enrollment: 2023 Feb 03
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

F198S Gerstmann-Sträussler-Scheinker Syndrome With Parkinsonism, Dyskinesia, and Abnormal (I-123)-FP-CIT Single-Photon Emission Computed Tomography: A Case Report.
Jiang, R., Aradi, S.> ;Cureus. 2023 Dec 1
Key Features in the Design and Function of Nanocarriers for Intranasal Administration of Gene Therapy in Huntington Disease.
Oksana Fihurka, Stephen Aradi, Vasyl Sava, Juan Sanchez-Ramos> ;Journal of Nanotechnology and Nanomaterials. 2023 Jan 1
HIV-associated dementia presenting predominantly with clinical motor deficits: A case report.
Laura McLean, Stephen Aradi, Roy Waknin, Brittany Rea, Marc A Camacho> ;Radiology Case Reports. 2022 Sep 1
1 citations
Predicting Severity of Huntington's Disease With Wearable Sensors.
Brittany H Scheid, Stephen Aradi, Robert M Pierson, Steven Baldassano, Inbar Tivon, Brian Litt, Pedro Gonzalez-Alegre> ;Frontiers in Digital Health. 2022 Jan 1
39 citations
Istradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson's disease.
Peter Jenner, Akihisa Mori, Stephen D. Aradi, Robert A. Hauser> ;Expert Review of Neurotherapeutics. 2021 Jan 28
22 citations
The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant.
Peter A. LeWitt, Stephen D. Aradi, Robert A. Hauser, Olivier Rascol> ;Parkinsonism & Related Disorders. 2020 Nov 1
36 citations
Medical Management and Prevention of Motor Complications in Parkinson’s Disease
Stephen D. Aradi, Robert A. Hauser> ;Neurotherapeutics. 2020 Oct 1
31 citations
Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report.
Stephen Aradi, Eric A. Kaiser, Brett Cucchiara> ;Journal of Stroke and Cerebrovascular Diseases. 2019 Jul 18
Clinical Reasoning: A man with rapidly ascending paralysis
Jon Rosenberg, Stephen Aradi, Amy A. Pruitt> ;Neurology. 2017 Jul 25
Join now to see all

Books/Book Chapters

Decision-Making in Adult Neurology
Chapter: Dysarthria
Page 48 - 49Stephen Aradi, Brett L. CucchiaraEditors: Brett L. Cucchiara, Raymond S. Price.Elsevier, St. LouisEdition 1st,2021

Abstracts/Posters

Automatic classification of abnormal movement in Huntington’s disease using wearable sensors and machine learning
S. Aradi, R. Pierson, B. Scheid, S. Baldassano, B. Litt, P. Gonzalez-Alegre, MDS 2020, 2020

Other

Pharmacologic pupil: The “blown pupil” of a healthy patient; June 5, 2017 e-Pearl of the Week
Stephen Aradi
https://n.neurology.org/epearls/20170605
6/5/2017

Press Mentions

The Challenge of Developing Adenosine A2A Antagonists for Parkinson Disease: Istradefylline, Preladenant, and TozadenantDecember 18th, 2020
Getting a Medical Education from Your HeadphonesJanuary 23rd, 2017